ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN
Status:
Not yet recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This is research study to find out if a drug called ADCT-301 is safe and to look at how
patients respond to the study drug after an allogeneic transplantation.
ADCT-301 will be administered on Days 1, 8 and 15 with blood tests following study drug
infusion. Patients will have a bone marrow biopsy at the end of cycle 2/before cycle 3 to see
how they are responding to the study drug.
Patients will be followed for approximately every 12 weeks from the last disease assessment
for up to 1 year from completion of therapy.
There are risks to this study drug. Some risks include: decrease in certain blood cells,
weight loss, loss of appetite, rash and Guillain-Barre syndrome, where the immune system
attacks and damages nerves.